{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:39:31Z","timestamp":1787582371735,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pancreatic ductal adenocarcinoma is characterized by therapy resistance and an immunosuppressive microenvironment. This study investigated the cellular mechanisms underlying chemotherapy resistance and immune evasion in PDAC, focusing on identifying key malignant epithelial subpopulations and their molecular drivers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed scRNA-seq data from 27 samples, including treatment-naive and chemotherapy-exposed primary tumors and liver metastasis. Analysis included CNV inference, gene set enrichment, cell\u2013cell communication, NMF analysis and drug sensitivity prediction. Validation employed gemcitabine-resistant cells, western blotting and pan-cancer survival analysis of TCGA\/ICGC data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified a malignant epithelial subcluster enriched in progressive disease samples and liver metastasis. This subcluster exhibited an immune-cold phenotype, characterized by disrupted communication with immune cells, increased immunosuppressive regulatory T cells and exclusion of anti-tumor effector cells. Further, it was associated with activated oncogenic and chemoresistance pathways, multi-drug resistance to standard therapies, higher tumor mutational burden and increased KRAS mutation frequency.\n                      <jats:italic>RARRES1<\/jats:italic>\n                      was nominated as a core upregulated gene in this subpopulation. Functional studies confirmed\n                      <jats:italic>RARRES1<\/jats:italic>\n                      overexpression in gemcitabine-resistant cells, and pan-cancer analysis established\n                      <jats:italic>RARRES1<\/jats:italic>\n                      as a new biomarker for poor prognosis across multiple cancer types.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Our work defines a chemotherapy-resistant and metastasis-enriched malignant epithelial subpopulation in PDAC that drives disease progression through an immune-cold niche. We identify\n                      <jats:italic>RARRES1<\/jats:italic>\n                      as a pivotal regulator of this process, contributing to both therapy resistance and immune exclusion, and propose it as a novel pan-cancer prognostic biomarker. These findings reveal a targetable cellular mechanism underlying poor treatment response in PDAC.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00262-026-04361-8","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:14:08Z","timestamp":1773922448000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["RARRES1 marks an immune-cold, chemoresistance-associated malignant epithelial subpopulation enriched in pancreatic ductal adenocarcinoma"],"prefix":"10.1007","volume":"75","author":[{"given":"Heming","family":"Ge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarik","family":"Ghadban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerrit","family":"Wolters-Eisfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thilo","family":"Hackert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cenap","family":"G\u00fcng\u00f6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"4361_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74:12\u201349. https:\/\/doi.org\/10.3322\/caac.21820","journal-title":"CA Cancer J Clin"},{"key":"4361_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17020204","author":"J Ye","year":"2025","unstructured":"Ye J, Qin SS, Hughson AL et al (2025) Blockade of LIF and PD-L1 enhances chemotherapy in preclinical PDAC models. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers17020204","journal-title":"Cancers (Basel)"},{"key":"4361_CR3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.49720","volume":"6","author":"BM Huffman","year":"2023","unstructured":"Huffman BM, Basu Mallick A, Horick NK et al (2023) Effect of a MUC5AC antibody (NPC-1C) administered with second-line Gemcitabine and Nab-Paclitaxel on the survival of patients with advanced pancreatic ductal adenocarcinoma: a randomized clinical trial. JAMA Netw Open 6:e2249720. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.49720","journal-title":"JAMA Netw Open"},{"key":"4361_CR4","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00092","volume":"7","author":"JCF Quintanilha","year":"2023","unstructured":"Quintanilha JCF, Storandt MH, Graf RP et al (2023) Tumor mutational burden in real-world patients with pancreatic cancer: genomic alterations and predictive value for immune checkpoint inhibitor effectiveness. JCO Precis Oncol 7:e2300092. https:\/\/doi.org\/10.1200\/PO.23.00092","journal-title":"JCO Precis Oncol"},{"key":"4361_CR5","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241259635","volume":"16","author":"A Demaziere","year":"2024","unstructured":"Demaziere A, Mourgues C, Lambert C et al (2024) French multi-institutional cost-effectiveness analysis of gemcitabine plus Nab-Paclitaxel versus gemcitabine alone as second-line treatment in metastatic pancreatic cancer patients. Ther Adv Med Oncol 16:17588359241259635. https:\/\/doi.org\/10.1177\/17588359241259635","journal-title":"Ther Adv Med Oncol"},{"key":"4361_CR6","doi-asserted-by":"publisher","first-page":"5623","DOI":"10.1038\/s41467-021-25921-9","volume":"12","author":"D Osuna de la Pena","year":"2021","unstructured":"Osuna de la Pena D, Trabulo SMD, Collin E et al (2021) Bioengineered 3D models of human pancreatic cancer recapitulate in vivo tumour biology. Nat Commun 12:5623. https:\/\/doi.org\/10.1038\/s41467-021-25921-9","journal-title":"Nat Commun"},{"key":"4361_CR7","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1158\/1078-0432.CCR-14-1429","volume":"21","author":"M Jamal-Hanjani","year":"2015","unstructured":"Jamal-Hanjani M, Quezada SA, Larkin J et al (2015) Translational implications of tumor heterogeneity. Clin Cancer Res 21:1258\u20131266. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-1429","journal-title":"Clin Cancer Res"},{"key":"4361_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-022-02408-z","volume":"41","author":"X Zhou","year":"2022","unstructured":"Zhou X, Zhang J, Lv W et al (2022) The pleiotropic roles of adipocyte secretome in remodeling breast cancer. J Exp Clin Cancer Res 41:203. https:\/\/doi.org\/10.1186\/s13046-022-02408-z","journal-title":"J Exp Clin Cancer Res"},{"key":"4361_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1253586","volume":"14","author":"S Xiong","year":"2023","unstructured":"Xiong S, Li S, Zeng J et al (2023) Deciphering the immunological and prognostic features of bladder cancer through platinum-resistance-related genes analysis and identifying potential therapeutic target P4HB. Front Immunol 14:1253586. https:\/\/doi.org\/10.3389\/fimmu.2023.1253586","journal-title":"Front Immunol"},{"key":"4361_CR10","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1200\/JCO.21.02616","volume":"40","author":"N Ullman","year":"2022","unstructured":"Ullman N, Burchard P, Dunne R et al (2022) Immunologic strategies in pancreatic cancer: making cold tumors hot. J Clin Oncol 40:2789\u20132805. https:\/\/doi.org\/10.1200\/JCO.21.02616","journal-title":"J Clin Oncol"},{"key":"4361_CR11","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/ng.3398","volume":"47","author":"RA Moffitt","year":"2015","unstructured":"Moffitt RA, Marayati R, Flate EL et al (2015) Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet 47:1168\u20131178. https:\/\/doi.org\/10.1038\/ng.3398","journal-title":"Nat Genet"},{"key":"4361_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202408751","volume":"12","author":"RF Li","year":"2025","unstructured":"Li RF, Liu S, Gao Q et al (2025) Inhibition of CDH11 activates cGAS-STING by stimulating branched chain amino acid catabolism and mitigates lung metastasis of adenoid cystic carcinoma. Adv Sci (Weinh) 12:e2408751. https:\/\/doi.org\/10.1002\/advs.202408751","journal-title":"Adv Sci (Weinh)"},{"key":"4361_CR13","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41467-023-36296-4","volume":"14","author":"G Werba","year":"2023","unstructured":"Werba G, Weissinger D, Kawaler EA et al (2023) Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment. Nat Commun 14:797. https:\/\/doi.org\/10.1038\/s41467-023-36296-4","journal-title":"Nat Commun"},{"key":"4361_CR14","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1016\/j.cell.2024.06.038","volume":"187","author":"Y Yang","year":"2024","unstructured":"Yang Y, Chen X, Pan J et al (2024) Pan-cancer single-cell dissection reveals phenotypically distinct B cell subtypes. Cell 187:4790\u2013811 e22. https:\/\/doi.org\/10.1016\/j.cell.2024.06.038","journal-title":"Cell"},{"key":"4361_CR15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1126\/science.aad0501","volume":"352","author":"I Tirosh","year":"2016","unstructured":"Tirosh I, Izar B, Prakadan SM et al (2016) Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352:189\u2013196. https:\/\/doi.org\/10.1126\/science.aad0501","journal-title":"Science"},{"key":"4361_CR16","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/s41467-021-21246-9","volume":"12","author":"S Jin","year":"2021","unstructured":"Jin S, Guerrero-Juarez CF, Zhang L et al (2021) Inference and analysis of cell-cell communication using Cell Chat. Nat Commun 12:1088. https:\/\/doi.org\/10.1038\/s41467-021-21246-9","journal-title":"Nat Commun"},{"key":"4361_CR17","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR et al (2015) Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 12:453\u2013457. https:\/\/doi.org\/10.1038\/nmeth.3337","journal-title":"Nat Methods"},{"key":"4361_CR18","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.ccell.2024.06.009","volume":"42","author":"Y Chen","year":"2024","unstructured":"Chen Y, Wang D, Li Y et al (2024) Spatiotemporal single-cell analysis decodes cellular dynamics underlying different responses to immunotherapy in colorectal cancer. Cancer Cell 42:1268\u201385 e7. https:\/\/doi.org\/10.1016\/j.ccell.2024.06.009","journal-title":"Cancer Cell"},{"key":"4361_CR19","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nbt.2859","volume":"32","author":"C Trapnell","year":"2014","unstructured":"Trapnell C, Cacchiarelli D, Grimsby J et al (2014) The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. Nat Biotechnol 32:381\u2013386. https:\/\/doi.org\/10.1038\/nbt.2859","journal-title":"Nat Biotechnol"},{"key":"4361_CR20","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.1158\/0008-5472.CAN-11-0036","volume":"71","author":"C G\u00fcng\u00f6r","year":"2011","unstructured":"G\u00fcng\u00f6r C, Zander H, Effenberger KE et al (2011) Notch signaling activated by replication stress-induced expression of midkine drives epithelial-mesenchymal transition and chemoresistance in pancreatic cancer. Cancer Res 71:5009\u20135019. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-0036","journal-title":"Cancer Res"},{"key":"4361_CR21","doi-asserted-by":"publisher","first-page":"6119","DOI":"10.1016\/j.cell.2021.11.017","volume":"184","author":"S Raghavan","year":"2021","unstructured":"Raghavan S, Winter PS, Navia AW et al (2021) Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Cell 184:6119\u201337 e26. https:\/\/doi.org\/10.1016\/j.cell.2021.11.017","journal-title":"Cell"},{"key":"4361_CR22","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1038\/s43018-022-00470-2","volume":"3","author":"F Cappellesso","year":"2022","unstructured":"Cappellesso F, Orban MP, Shirgaonkar N et al (2022) Targeting the bicarbonate transporter SLC4A4 overcomes immunosuppression and immunotherapy resistance in pancreatic cancer. Nat Cancer 3:1464\u20131483. https:\/\/doi.org\/10.1038\/s43018-022-00470-2","journal-title":"Nat Cancer"},{"key":"4361_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2013.6","volume":"2","author":"EE Oldridge","year":"2013","unstructured":"Oldridge EE, Walker HF, Stower MJ et al (2013) Retinoic acid represses invasion and stem cell phenotype by induction of the metastasis suppressors RARRES1 and LXN. Oncogenesis 2:e45. https:\/\/doi.org\/10.1038\/oncsis.2013.6","journal-title":"Oncogenesis"},{"key":"4361_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/cells11050848","author":"A Divoux","year":"2022","unstructured":"Divoux A, Erdos E, Whytock K et al (2022) Transcriptional and DNA methylation signatures of subcutaneous adipose tissue and adipose-derived stem cells in PCOS women. Cells. https:\/\/doi.org\/10.3390\/cells11050848","journal-title":"Cells"},{"key":"4361_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-022-01059-0","volume":"15","author":"D Zhang","year":"2022","unstructured":"Zhang D, Lu W, Cui S et al (2022) Establishment of an ovarian cancer omentum metastasis-related prognostic model by integrated analysis of scRNA-seq and bulk RNA-seq. J Ovarian Res 15:123. https:\/\/doi.org\/10.1186\/s13048-022-01059-0","journal-title":"J Ovarian Res"},{"key":"4361_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.982045","volume":"13","author":"X Geng","year":"2022","unstructured":"Geng X, Chi K, Liu C et al (2022) Interaction of RARRES1 with ICAM1 modulates macrophages to suppress the progression of kidney renal clear cell carcinoma. Front Immunol 13:982045. https:\/\/doi.org\/10.3389\/fimmu.2022.982045","journal-title":"Front Immunol"},{"key":"4361_CR27","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.7150\/ijbs.69615","volume":"18","author":"J Patel","year":"2022","unstructured":"Patel J, Xun D, Creswell K et al (2022) Loss of RARRES1 function promotes follicular lymphomagenesis and inhibits B cell differentiation in mice. Int J Biol Sci 18:2670\u20132682. https:\/\/doi.org\/10.7150\/ijbs.69615","journal-title":"Int J Biol Sci"},{"key":"4361_CR28","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.kint.2024.04.011","volume":"106","author":"Y Feng","year":"2024","unstructured":"Feng Y, Sun Z, Fu J et al (2024) Podocyte-derived soluble RARRES1 drives kidney disease progression through direct podocyte and proximal tubular injury. Kidney Int 106:50\u201366. https:\/\/doi.org\/10.1016\/j.kint.2024.04.011","journal-title":"Kidney Int"},{"key":"4361_CR29","doi-asserted-by":"publisher","first-page":"9380","DOI":"10.3390\/ijms13079380","volume":"13","author":"HL Chen","year":"2012","unstructured":"Chen HL, Seol H, Brown KJ et al (2012) Secretome survey of human plexiform neurofibroma derived Schwann cells reveals a secreted form of the RARRES1 protein. Int J Mol Sci 13:9380\u20139399. https:\/\/doi.org\/10.3390\/ijms13079380","journal-title":"Int J Mol Sci"},{"key":"4361_CR30","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1159\/000520803","volume":"107","author":"L Ma","year":"2022","unstructured":"Ma L, Ma Y, Lian A (2022) Involvement of miR-769-5p\/retinoic acid receptor responder 1 axis in the progression of osteosarcoma: characterization of potential therapeutic targets. Pharmacology 107:179\u2013187. https:\/\/doi.org\/10.1159\/000520803","journal-title":"Pharmacology"},{"key":"4361_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-65032-1","volume":"14","author":"M Liu","year":"2024","unstructured":"Liu M, Bai R, Zhang G et al (2024) RARRES1 identified by comprehensive bioinformatic analysis and experimental validation as a promising biomarker in skin cutaneous melanoma. Sci Rep 14:14113. https:\/\/doi.org\/10.1038\/s41598-024-65032-1","journal-title":"Sci Rep"},{"key":"4361_CR32","doi-asserted-by":"publisher","first-page":"6516","DOI":"10.1158\/0008-5472.CAN-13-0967","volume":"73","author":"X Wang","year":"2013","unstructured":"Wang X, Saso H, Iwamoto T et al (2013) TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase. Cancer Res 73:6516\u20136525. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-0967","journal-title":"Cancer Res"},{"key":"4361_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s13062-024-00459-0","volume":"19","author":"Y Guo","year":"2024","unstructured":"Guo Y, Chai B, Zhang H et al (2024) RARRES1 inhibits hepatocellular carcinoma progression and increases its sensitivity to lenvatinib through interaction with SPINK2. Biol Direct 19:15. https:\/\/doi.org\/10.1186\/s13062-024-00459-0","journal-title":"Biol Direct"},{"key":"4361_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1410463","volume":"15","author":"S Fu","year":"2024","unstructured":"Fu S, Qian M, Yuan Z et al (2024) A new perspective on selenium\u2019s impact on renal function: European population-based analysis of plasma proteome-mediated Mendelian randomization study. Front Endocrinol (Lausanne) 15:1410463. https:\/\/doi.org\/10.3389\/fendo.2024.1410463","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4361_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14184405","author":"C Nitschke","year":"2022","unstructured":"Nitschke C, Markmann B, Tolle M et al (2022) Characterization of RARRES1 expression on circulating tumor cells as unfavorable prognostic marker in resected pancreatic ductal adenocarcinoma patients. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14184405","journal-title":"Cancers (Basel)"},{"key":"4361_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01736-9","volume":"18","author":"YR Li","year":"2025","unstructured":"Li YR, Shen X, Zhu Y et al (2025) Targeting triple-negative breast cancer using cord-blood CD34(+) HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity. J Hematol Oncol 18:86. https:\/\/doi.org\/10.1186\/s13045-025-01736-9","journal-title":"J Hematol Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04361-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04361-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04361-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:14:09Z","timestamp":1773922449000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04361-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["4361"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04361-8","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"5 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"115"}}